Zoetis Scientists Present Positive Efficacy Data for Investigational Triple Combination Parasiticide at American Heartworm So...
September 09 2019 - 4:30PM
Business Wire
Triple combination product contains sarolaner,
moxidectin and pyrantel
Zoetis Inc. today announced that its scientists presented
positive efficacy data for the company’s investigational, triple
combination parasiticide product at the 2019 Triennial meeting of
the American Heartworm Society (AHS) in New Orleans, La. Zoetis is
developing a triple combination product containing sarolaner,
moxidectin and pyrantel that is administered orally once a month as
a preventative for heartworm disease and to treat and control
ticks, fleas, and intestinal nematodes in dogs.
The results from effectiveness studies in dogs treated with the
combination product demonstrated that no adult heartworms were
recovered from animals in the laboratory studies and no positive
test results for adult heartworms were obtained from dogs in the
field study. The product was well-tolerated in all studies
presented.
In addition, data from a separate study, which tested the
efficacy of oral moxidectin at doses ranging from 3 to 60 µg/kg
against three confirmed macrocyclic lactone resistant heartworm
strains, served as the basis for selecting the dose of moxidectin
included in the investigational combination product. In this study,
moxidectin at 24µg/kg given monthly for three consecutive months
demonstrated a high level of efficacy in reducing the development
of heartworms in these dogs.
Dr. Tom McTier, Research Director and Therapeutic Area Head for
Companion Animal Parasitology, Zoetis Veterinary Medicine Research
and Development, and one of the AHS presenters stated, “Independent
investigators have confirmed that multiple strains of D. immitis
that are resistant to macrocyclic lactones have been identified in
the U.S. (1-6). Our data support the decision to use a 24
µg/kg dose of moxidectin in our investigational combination
product.”
The abstracts are available to conference attendees only at this
time, but Zoetis has submitted these papers to be published in
peer-reviewed scientific journals and expects them to be available
publicly in the coming weeks.
As previously disclosed in its second quarter earnings, Zoetis’
combination parasiticide product is in regulatory review in the
U.S., Canada, Brazil, Australia and Japan, as well as with the
European Medicines Agency. If approved, the company anticipates
this product coming to market in 2020.
About Heartworm Disease
Canine heartworm disease is a serious, potentially fatal
condition that can result in severe lung disease, heart failure and
damage to other internal organs. The disease is caused by a
filarial parasite, Dirofilaria immitis, which is transmitted to
dogs though the bite of an infected mosquito. Adult worms live in
the heart, lungs and associated blood vessels of an infected animal
(7). The Companion Animal Parasite Council (CAPC) recommends
annual heartworm testing and prevention of heartworm infection
though the use of year round preventatives in all dogs
(8).
About Zoetis
Zoetis is the leading animal health company, dedicated to
supporting its customers and their businesses. Building on more
than 65 years of experience in animal health, Zoetis discovers,
develops, manufactures and commercializes medicines, vaccines and
diagnostic products, which are complemented by biodevices, genetic
tests and a range of services. Zoetis serves veterinarians,
livestock producers and people who raise and care for farm and
companion animals with sales of its products in more than 100
countries. In 2018, the company generated annual revenue of $5.8
billion with approximately 10,000 employees. For more information,
visit www.zoetis.com.
DISCLOSURE NOTICES
Forward-Looking Statements: This
press release contains forward-looking statements, which reflect
the current views of Zoetis with respect to business plans or
prospects, expectations regarding products, regulatory approvals
and other future events. These statements are not guarantees of
future performance or actions. Forward-looking statements are
subject to risks and uncertainties. If one or more of these risks
or uncertainties materialize, or if management's underlying
assumptions prove to be incorrect, actual results may differ
materially from those contemplated by a forward-looking statement.
Forward-looking statements speak only as of the date on which they
are made. Zoetis expressly disclaims any obligation to update or
revise any forward-looking statement, whether as a result of new
information, future events or otherwise. A further list and
description of risks, uncertainties and other matters can be found
in our Annual Report on Form 10-K for the fiscal year ended
December 31, 2018, including in the sections thereof captioned
“Forward-Looking Statements and Factors That May Affect Future
Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on
Form 10-Q and in our Current Reports on Form 8-K. These filings and
subsequent filings are available online at www.sec.gov,
www.zoetis.com, or on request from Zoetis.
References (as of August 26th)
- Pulaski CN, Malone JB, Bourguinat C, Prichard R, Geary T, Ward
DR, et al. Establishment of macrocyclic lactone resistant
Dirofilaria immitis isolates in experimentally infected laboratory
dogs. Parasit Vectors. 2014;7:494.
- Bourguinat C, Lee A, Lizunda R, Blagburn B, Liotta J, Kraus M,
et al. Macrocyclic lactone resistance in Dirofilaria immitis:
failure of heartworm preventives and investigation of genetic
markers for resistance. Vet Parasitol. 2015:210;167–78.
- Maclean MJ, Savadelis MD, Coates R, Dzimianski M, Jones C,
Benbow C, et al. Does evaluation of in vitro microfiliarial
motility reflect the resistance status of Dirofilaria immitis
isolates to macrocyclic lactones? Parasit Vectors. 2017:10(Suppl.
2);480.
- Blagburn BL, Arther RG, Dillon AR, Butler JM, Bowles JV, von
Simpson C, Zolynas R. Efficacy of four commercially available
heartworm preventive products against the JYD-34 laboratory strain
of Dirofilaria immitis. Parasit Vectors. 2016:9;191.
- McTier TL, Six RH, Pullins A, Chapin S, McCall JW, Rugg D, et
al. Efficacy of oral moxidectin against susceptible and resistant
isolates of Dirofilaria immitis in dogs. Parasit Vectors.
2017:10(Suppl. 2);482.
- Ballesteros C, Pulaski C N, Bourguinat C, Keller K, Prichard
RK, Geary TG. Clinical validation of molecular markers of
macrocyclic lactone resistance in Dirofilaria immitis. Int J
Parasitol Drugs Drug Resist. 2018;8:596–606.
- www.fda.gov/animal-veterinary-literacy/keep-worms-out -your
pets-heart-facts-about-heartworm-disease
- www.capcvet.org/guidelines/heartworm
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190909005871/en/
Media: Bill Price 1-973-443-2742
(o) william.price@zoetis.com Kristen Seely 1-973-443-2777 (o)
kristen.seely@zoetis.com Investor:
Steve Frank 1-973-822-7141 (o) steve.frank@zoetis.com Marissa Patel
1-973-443-2996 (o) marissa.patel@zoetis.com
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Jul 2023 to Jul 2024